RxDoctor Payments DataLook up a doctor →

Benjamin Ungar, MD

Dermatology · New York, NYNPI 1912435462

Payments from drug & device makers

$1,731,511in general payments, 2019–2025

Across 750 payments — averaging $2308.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$861K
  • Incyte Corporation$556K
  • Pfizer$178K
  • Eli Lilly$31K
  • Galderma Laboratories, L.p.$24K
  • AbbVie$16K
  • plus $65K from 25 others
$940in research payments, 2019–2025

Across 1 payment — averaging $940.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$940

What the payments were for

  • Consulting fees$119,01276%
  • Speaking & faculty fees$17,53211%
  • Travel & lodging$4,4903%
  • Food & beverage$16,05510%
  • Education$950%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,731,511 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$89,436
Medicare patients
289
Services billed
2,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab47$164,293
Taltz AutoinjectorIxekizumab12$103,337
Dupixent SyringeDupilumab26$89,033
OlumiantBaricitinib11$57,216
OpzeluraRuxolitinib Phosphate19$40,400
Tacrolimus57$9,795
QbrexzaGlycopyrronium Tosylate13$9,529
Clobetasol Propionate172$8,816
Doxycycline Hyclate22$2,848
Ketoconazole77$2,207
Minoxidil167$2,159
Tretinoin19$1,934
Calcipotriene14$1,288
Triamcinolone Acetonide36$394
Clindamycin Phosphate13$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$5,010$57,21611 claims
Incyte CorporationOpzelura$556,377$40,40019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →